Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To determine the prevalence of neuropathic pain in PD and association between neuropathic pain, duration of PD, treatment with Levodopa, cumulative dose, non-motor symptoms and quality of life.
Background: Parkinson’s disease is the second most common neurodegenerative disorder. It has a wide range of non-motor features, including anosmia, sleep disturbances, constipation, change in mood and pain. There is a growing interest in evaluating if peripheral neuropathy is more common in PD, if part of the process of the disease or a complication of levodopa therapy. The frequency of peripheral neuropathy in PD patients treated with levodopa varies from 4.8% to 55%. It is likely that the accumulation of methylmalonic acid or relative deficiency of cobalamin causes peripheral neuropathy.
Methods: A Cross-sectional study with patients diagnosed with PD. A structured-interview was applied to all subjects, validated questionnaires for detection of neuropathic pain: LANSS, DN4, as well KING PD scale was used. And different clinical characteristics as gender, age, levodopa, LEDD, scale MDS-UPDRS, NMSS scale and PDQ-8. Bivariate analysis was performed using nonparametric Kruskal-Wallis, Mann-whitney “U” and Chi-square test.
Results: A total of 57 patients were obtained. The female gender was predominant with 54.4%, the mean age was 63.07 ± 12.06 years and disease duration was 7.00 ± 6.21 years. Within the ranges for detecting neuropathic pain, LANSS detect achievement in 7% of the patients while in DN4 26.3%. Statistical significance was found in the association of the DN4 scale and NMSS scale (p = 0.010) and PDQ-8 (p = 0.026). There was an association of KING-PD scale in the Domain 7 with the PDQ-8 level and the H&Y stages with a statistical significance of p=0.008 and p= 0.002 respectively. By measuring the progression of disease as stadiums H&Y, a statistically significant association with scales for detecting neuropathic pain, DN4 scale with p = 0.006, LANSS with p= 0.006 and KING-PD with a p= 0.025 was found.
Conclusions: The study shows no association between treatment, LEDD and neuropathy. The prevalence of neuropathic pain in PD founded in our patients was similar that reported in the literature. There is a relationship between the progression of PD and the prevalence and severity of neuropathic pain, along with a partnership between the scale of NMSS and PDQ-8 with the presence of neuropathic pain.
To cite this abstract in AMA style:J.F. Pascacio-Astudillo, A.L. Bazàn-Rodrìguez, M. Rodrìguez-Violante, A. Cervantes-Arriaga. Frequency and factors associated with neuropathic pain in patients with Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/frequency-and-factors-associated-with-neuropathic-pain-in-patients-with-parkinsons-disease/. Accessed December 7, 2023.
« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/frequency-and-factors-associated-with-neuropathic-pain-in-patients-with-parkinsons-disease/